Drugs / [64Cu]Cu-AKY-2519
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07581184 | Jul 2026 → Dec 2027 expected | castration-resistant prostate carcinoma | Aktis Oncology, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [64Cu]Cu-AKY-2519 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07581184 ↗ |
| Modality | Diagnostic / imaging agent | “[64Cu]Cu-AKY-2519 (imaging)” NCT07581184 ↗ |